Vast Funding is Available for the Later Stages of Development of any Credible Therapy that Addresses a Cause of Aging

Today I'll point out a couple of recent news items that illustrate there is no funding drought for any group that manages to bring a credible approach to addressing one of the causes of aging to the point of human clinical trials. This is the case even when it is generally understood by all involved that the therapies in question are first generation attempts at implementation, subject to all the normal challenges that brings, and in principle not as good as competing forms of technology that are still at an earlier stage in the process of development. The drought lies in the number of groups who can make it to this stage, because there are never enough entrepreneurs, and the issues with fundraising are all further back in the pipeline: it is hard to raise funds for research into most means of rejuvenation, and it is hard to raise funds at the early startup stage, though that second point is rapidly becoming easier with the growth in the number of incubators focused on biotechnology and aging. Look at YC Bio, for example, or Age 1. (That it takes a ridiculous amount of funding to pass regulatory hurdles on the way to the clinic is an entire and separate topic for discussion. The task of proving that a treatment works and quantifying the risk of using it to a satisfactory level simply doesn't cost more than a small fraction of the amount that the FDA forces it to cost. Everything above that much lower amount is unnecessary waste, the standard corrosion of efficiency pro...
Source: Fight Aging! - Category: Research Authors: Tags: Investment Source Type: blogs